Latest fiscal year 2024 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2024, Clearside Biomedical, Inc. reported revenue of $2M, down 79.8% year over year. Operating margin was -1735.7% and net margin -2064.4%, on a free-cash-flow margin of -1543.0% with capital expenditure at 58.7% of revenue. Every figure is computed directly from CLSDQ's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2024 | $2M | -1735.7% | -2064.4% |
| FY2023 | $8M | -302.0% | -394.9% |
| FY2022 | $1M | -2281.6% | -2482.8% |
| FY2021 | $30M | -2.1% | 1.3% |
| FY2020 | $8M | -227.2% | -230.7% |
How does CLSDQ compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.